Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current Treatment Options for Adult Grade 2 IDH-mutant Diffuse Gliomas in the Vorasidenib Era: Patient Selection, Sequencing, and Practical Management.

Current treatment options in oncology - 10 Jul 2026

Wu Jianheng, Wang Nannan

Abstract excerpt

OPINION STATEMENT: Management of adult WHO CNS grade 2 IDH-mutant diffuse gliomas has entered a more precise postoperative era. Vorasidenib has changed the discussion because it can slow progression and delay the next intervention in selected patients, but the key therapeutic question is not whether mutant IDH inhibition is active; it is where it should be placed relative to observation, reoperation,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Clinical Decision-Making

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Disease Management

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Neoplasm Grading

Share to Patient Selection

Source

Identifiers

PMID: 42430039
DOI: 10.1007/s11864-026-01401-4

Genes

CDKN2A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current Treatment Options for Adult Grade 2 IDH-mutant Diffuse Gliomas in the Vorasidenib Era: Patient Selection, Sequencing, and Practical Management.PMID 42430039Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

Treatment Options for IDH-Mutant Malignant Gliomas.Semantic proximity Read ↗

Advances in the treatment of IDH-mutant gliomas.Semantic proximity Read ↗

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaSemantic proximity Read ↗

Vorasidenib: First Approval.Semantic proximity Read ↗

Adult-type Diffuse Gliomas.Semantic proximity Read ↗

Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomasSemantic proximity Read ↗

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.Semantic proximity Read ↗

IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse GliomasSemantic proximity Read ↗

Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics.Semantic proximity Read ↗

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.Semantic proximity Read ↗

Conventional and emerging treatments of astrocytomas and oligodendrogliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.